Idiosyncratic drug-induced liver injury: an overview

Bibliography

• DOSSING M, SONNE J: Drug-induced hepatic disorders. Incidence, management and avoidance. Drug Saf. (1993) 9:441-449.
   PubMed Web of Science ®Google Scholar
• FRIIS H, ANDREASEN PB: Drug-induced hepatic injury. An analysis of 1100 cases reported to the Danish committee on adverse drug reactions between 1978 and 1987. J. Intern. Med. (1992) 232:133-138.
   PubMed Web of Science ®Google Scholar
• MITCHELL JR, JOLLOW DJ, POTTER WZ, DAVIS DC, GILLETTE JR, BRODIE BB: Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J. Pharmacol. Exp. Ther. (1973) 187:211-217.
   PubMed Web of Science ®Google Scholar
• LEE WM: Drug-induced hepatotoxicity. N. Engl. J. Med. (2003) 349:474-485.
   PubMed Web of Science ®Google Scholar
• BENICHOU C: Criteria of drug-induced liver disorders. Report of an international consensus meeting. Hepatology (1990) 11:272-276.
   Web of Science ®Google Scholar
• ABBOUD G, KAPLOWITZ N: Drug-induced liver injury. Drug Saf. (2007) 30(4):277-294.
   PubMed Web of Science ®Google Scholar
• BJORNSSON E, OLSSON R: Outcome and prognostic markers in severe drug-induced liver disease. Hepatology (2005) 42:481-489.
   PubMed Web of Science ®Google Scholar
• WATKINS PB, SEEFF LB: Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology (2006) 43:618-631.
   PubMed Web of Science ®Google Scholar
• DESMET VJ: Vanishing bile duct syndrome in drug-induced liver disease. J. Hepatol. (1997) 26(Suppl. 1):31-35.
   PubMed Web of Science ®Google Scholar
• DEGOTT C, FELDMANN G, LARREY D et al.: Drug-induced prolonged cholestasis in adults: a histological semi quantitative study demonstrating progressive ductopenia. Hepatology (1992) 15:244-251.
   PubMed Web of Science ®Google Scholar
• KNOWLES SR, UETRECHT J, SHEAR NH: Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet (2000) 356:1587-1591.
   PubMed Web of Science ®Google Scholar
• PESSAYRE D, BERSON A, FROMENTY B, MANSOURI A: Mitochondria in steatohepatitis. Semin. Liver Dis. (2001) 21:57-69.
   PubMed Web of Science ®Google Scholar
• DANAN G, BENICHOU C: Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol. (1993) 46:1323-1330.
   PubMed Web of Science ®Google Scholar
• BENICHOU C, DANAN G, FLAHAULT A: Causality assessment of adverse reactions to drugs–II. An original model for validation of drug causality assessment methods: case reports with positive rechallange. J. Clin. Epidemiol. (1993) 46:1331-1336.
   PubMed Web of Science ®Google Scholar
• LUCENA MI, CAMARGO R, ANDRADE RJ, PEREZ-SANCHEZ CJ, SANCHEZ DE LA CUESTA F: Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology (2001) 33:123-130.
   PubMed Web of Science ®Google Scholar
• WATKINS PB, ZIMMERMAN HJ, KNAPP MJ, GRACON SI, LEWIS KW: Hepatotoxicity effects of tacrine administration in patients with Alzheimer's disease. JAMA (1994) 271:992-998.
   PubMed Web of Science ®Google Scholar
• NOLAN CM, GOLDBERG SV, BUSKIN SE: Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic. JAMA (1999) 17(281):1014-1018.
   Google Scholar
• OSTAPOWICZ G, FONTANA RJ, SCHIODT FV et al.: US acute liver failure study group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. (2002) 137:947-954.
   PubMed Web of Science ®Google Scholar
• BJORNSSON E, JERLSTAD P, BERGQVIST A, OLSSON R: Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. Scand. J. Gastroenterol. (2005) 40:1095-1101.
   PubMed Web of Science ®Google Scholar
• O'GRADY JG, ALEXANDER GJ, HAYLLAR KM, WILLIAMS R: Early indicators of prognosis in fulminant hepatic failure. Gastroenterology (1989) 97:439-445.
   PubMed Web of Science ®Google Scholar
• O'GRADY JG, WILLIAMS R: Classification of acute liver failure. Lancet (1993) 342:273-275.
   PubMed Web of Science ®Google Scholar
• DAVIDSON CS, LEEVY CM, CHAMBERLAYNE EC: Guidelines for detection of hepatotoxicity due to drugs and chemicals. Forgarthy conference, 1978. NIH publication no. 79-313. US Government Printing Office, Washington, DC, USA (1979).
   Google Scholar
• ZIMMERMAN HJ: Drug- induced liver disease. Clin. Liver Dis. (2000) 4:73-96.
   PubMedGoogle Scholar
• ANDRADE RJ, LUCENA MI, FERNANDEZ MC et al.: Spanish group for the study of drug-induced liver disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology (2005) 129:512-521.
   PubMed Web of Science ®Google Scholar
• OIKAWA H, MAESAWA C, SATO R et al.: Liver cirrhosis induced by long-term administration of a daily low dose of amiodarone: a case report. World J. Gastroenterol. (2005) 11(34):5394-5397.
   PubMed Web of Science ®Google Scholar
• PINEDA JA, LARRAURI J, MACIAS J et al.: Rapid progression to liver cirrhosis of toxic hepatitis due to ebrotidine. J. Hepatol. (1999) 31(4):777-778.
   PubMed Web of Science ®Google Scholar
• AITHAL PG, DAY CP: The natural history of histologically proved drug induced liver disease. Gut (1999) 44:731-735.
   PubMed Web of Science ®Google Scholar
• ANDRADE RJ, LUCENA MI, KAPLOWITZ N et al.: Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology (2006) 44:1581-1588.
   PubMed Web of Science ®Google Scholar
• BJORNSSON E, KALAITZAKIS E, AV KLINTEBERG V, ALEM N, OLSSON R: Long-term follow-up of patients with mild to moderate drug-induced liver injury. Aliment Pharmacol. Ther. (2007) 26:79-85.
   PubMed Web of Science ®Google Scholar
• SGRO C, CLINARD F, OUAZIR K et al.: Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology (2002) 36:451-455.
   PubMed Web of Science ®Google Scholar
• AITHAL PG, RAWLINS MD, DAY CP: Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ (1999) 319:1541.
   PubMed Web of Science ®Google Scholar
• LEMOZIT JP, DE LA RHODIERE GP, LAPEYRE-MESTRE M, BAGHERI H, MONTASTRUC JL: A comparative study of adverse drug reactions reported through hospital and private medicine. Br. J. Clin. Pharmacol. (1996) 41:166-168.
   PubMed Web of Science ®Google Scholar
• ELAND IA, BELTON KJ, VAN GROOTHEEST AC, MEINERS AP, RAWLINS MD, STRICKER BH: Attitudinal survey of voluntary reporting of adverse drug reactions. Br. J. Clin. Pharmacol. (1999) 48:623-627.
   PubMed Web of Science ®Google Scholar
• HUSSAINI SH, O'BRIEN CS, DESPOTT EJ, DALTON HR: Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. Eur. J. Gastroenterol. Hepatol. (2007) 19:15-20.
   PubMed Web of Science ®Google Scholar
• IBANEZ L, PEREZ E, VIDAL X, LAPORTE JR: Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J. Hepatol. (2002) 37:592-600.
   PubMed Web of Science ®Google Scholar
• DE VALLE MB, KLINTEBERG V, ALEM N, OLSSON R, BJORNSSON E: Drug-induced liver injury in a Swedish university hospital out-patient hepatology clinic. Aliment Pharmacol. Ther. (2006) 24:1187-1195.
   PubMed Web of Science ®Google Scholar
• MEIER Y, CAVALLARO M, ROOS M et al.: Incidence of drug-induced liver injury in medical inpatients. Eur. J. Clin. Pharmacol. (2005) 61:135-143.
   PubMed Web of Science ®Google Scholar
• CHANG CY, SCHIANO TD: Review article: drug hepatotoxicity. Aliment Pharmacol. Ther. (2007) 25:1135-1151.
   PubMed Web of Science ®Google Scholar
• O'DONOHUE JA, OIEN KA, DONALDSON P et al.: Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut (2000) 47:717-720.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Cholestatic jaundice with co-amoxiclav. Curr. Probl. Pharmacovigilance (1993) 19:2.
   Google Scholar
• LARREY D, VIAL T, MICALEFF A et al.: Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. Gut (1992) 33:368-371.
   PubMed Web of Science ®Google Scholar
• GARCIA RODRIGUEZ LA, STRICKER BH, ZIMMERMANN HI: Risk of acute liver injury associated with the combination of amoxicllin and clavulanic acid. Arch. Intern. Med. (1996) 156:1327-1332.
   PubMed Web of Science ®Google Scholar
• LUCENA MI, ANDRADE RJ, FERNANDEZ MC et al.: Spanish group for the study of drug-induced liver disease (Grupo de Estudio para las Hepatopatias Asociadas a Medicamentos (GEHAM)). Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain. Hepatology (2006) 44:850-856.
   PubMed Web of Science ®Google Scholar
• RUSSMANN S, KAYE JA, JICK SS, JICK H: Risk of cholestatic liver disease associated with flucloxacillin and flucloxacillin prescribing habits in the UK: cohort study using data from the UK general practice research database. Br. J. Clin. Pharmacol. (2005) 60:1-76.
   PubMed Web of Science ®Google Scholar
• DEVEREAUX BM, CRAWFORD DH, PURCELL P, POWELL LW, ROESER HP: Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? Eur. J. Clin. Pharmacol. (1995) 49:81-85.
   PubMed Web of Science ®Google Scholar
• JONES SF, SMITH RH: Quinolones may induce hepatitis. BMJ (1997) 314:869.
   PubMedGoogle Scholar
• HAUTEKEETE ML, KOCKX MM, NAEGELS S, HOLVOET JK, HUBENS H, KLOPPEL G: Cholestatic hepatitis related to quinolones: a report of two cases. J. Hepatol. (1995) 23:759-760.
   PubMed Web of Science ®Google Scholar
• VIAL T, BIOUR M, DESCOTES J, TREPO C: Antibiotic-associated hepatitis: update from 1990. Ann. Pharmacother. (1997) 31:204-220.
   PubMed Web of Science ®Google Scholar
• GARCIA RODRIGUEZ LA, WILLIAMS R, DERBY LE, DEAN AD, JICK H: Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch. Intern. Med. (1994) 14(154):311-316.
   Google Scholar
• MANOUKIAN AV, CARSON JL: Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention. Drug Saf. (1996) 15:64-71.
   PubMed Web of Science ®Google Scholar
• WALKER AM: Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal anti-inflammatory drugs. Arthritis Rheum. (1997) 40:201-208.
   PubMed Web of Science ®Google Scholar
• BJORKMAN D: Nonsteroidal anti-inflammatory drug-associated toxicity of the liver, lower gastrointestinal tract, and esophagus. Am. J. Med. (1998) 105:S17-S21.
   PubMedGoogle Scholar
• ALGERIA P, LIBRA L, CHANGES C: Celecoxib-induced cholestatic hepatotoxicity in a patient with cirrhosis. Ann. Intern. Med. (2002) 137:75.
   PubMed Web of Science ®Google Scholar
• HUSTER D, SCHUBERT C, BERR F, MOSSNER J, CACA K: Rofecoxib-induced cholestatic hepatitis: treatment with molecular adsorbent recycling system (MARS). J. Hepatol. (2002) 37:413-414.
   PubMed Web of Science ®Google Scholar
• BANKS AT, ZIMMERMAN HJ, ISHAK KG, HARTER JG: Diclofenac-associated hepatotoxicity: analysis of 180 cases reported to the food and drug administration as adverse reactions. Hepatology (1995) 22:820-827.
   PubMed Web of Science ®Google Scholar
• FONTANA RJ, MCCASHLAND TM, BENNER KG et al.: Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The acute liver failure study group. Liver Transpl. Surg. (1999) 5:480-484.
   PubMedGoogle Scholar
• HELFGOTT SM, SANDBERG-COOK J, ZAKIM D, NESTLER J: Diclofenac-associated hepatotoxicity. JAMA (1990) 264:2660-2662.
   PubMed Web of Science ®Google Scholar
• ALLHAT officers and coordinators for the ALLHAT collaborative research group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA (2002) 288:2998-3007.
   PubMed Web of Science ®Google Scholar
• TOLMAN KG: The liver and lovastatin. Am. J. Cardiol. (2002) 89:1374-1380.
   PubMed Web of Science ®Google Scholar
• PFEFFER MA, KEECH A, SACKS FM et al.: Safety and tolerability of pravastatin in long-term clinical trials: prospective pravastatin pooling (PPP) project. Circulation (2002) 105(20):2341-2346.
   PubMed Web of Science ®Google Scholar
• RUSSO MW, GALANKO JA, SHRESTHA R, FRIED MW, WATKINS P: Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. (2004) 10:1018-1023.
   PubMed Web of Science ®Google Scholar
• COHEN DE, ANANIA FA, CHALASANI N: National lipid association statin safety task force liver expert panel. An assessment of statin safety by hepatologists. Am. J. Cardiol. (2006) 97:C77-C81.
   PubMed Web of Science ®Google Scholar
• SULKOWSKI MS: Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin. Infect. Dis. (2004) 38(Suppl. 2):S90-S97.
   Web of Science ®Google Scholar
• ZUCKER SD, QIN X, ROUSTER SD et al.: Mechanism of indinavir-induced hyperbilirubinemia. Proc. Natl. Acad. Sci. USA (2001) 98:12671-12676.
   PubMed Web of Science ®Google Scholar
• SULKOWSKI MS, THOMAS DL, CHAISSON RE, MOORE RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA (2000) 283:74-80.
   PubMed Web of Science ®Google Scholar
• LAW WP, DORE GJ, DUNCOMBE CJ et al.: Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996 – 2001. AIDS (2003) 17:2191-2199.
   PubMed Web of Science ®Google Scholar
• KONTORINIS N, DIETERICH DT: Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin. Liver Dis. (2003) 23:173-182.
   PubMed Web of Science ®Google Scholar
• MANFREDI R, CALZA L, CHIODO F: Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine. HIV Clin. Trials (2005) 6:302-311.
   PubMed Web of Science ®Google Scholar
• SULKOWSKI MS, THOMAS DL, MEHTA SH, CHAISSON RE, MOORE RD: Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 35:182-189.
   PubMed Web of Science ®Google Scholar
• SAVES M, VANDENTORREN S, DAUCOURT V et al.: Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996 – 1998. Groupe d'Epidemiologie Clinique de Sida en Aquitaine (GECSA). AIDS (1999) 13:F115-F121.
   PubMed Web of Science ®Google Scholar
• SAVES M, RAFFI F, CLEVENBERGH P et al.: Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO study group. Antimicrob. Agents Chemother. (2000) 44:3451-3455.
   PubMed Web of Science ®Google Scholar
• DEN BRINKER M, WIT FW, WERTHEIM-VAN DILLEN PM et al.: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS (2000) 14:2895-2902.
   PubMed Web of Science ®Google Scholar
• GISOLF EH, DREEZEN C, DANNER SA, WEEL JL, WEVERLING GJ: Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus study group. Clin. Infect. Dis. (2000) 31:1234-1239.
   PubMed Web of Science ®Google Scholar
• NUNEZ M, LANA R, MENDOZA JL, MARTIN-CARBONERO L, SORIANO V: Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. (2001) 27:426-431.
   PubMed Web of Science ®Google Scholar
• BONFANTI P, LANDONIO S, RICCI E et al.: Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. (2001) 27:316-318.
   PubMed Web of Science ®Google Scholar
• WIT FW, WEVERLING GJ, WEEL J, JURRIAANS S, LANGE JM: Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J. Infect. Dis. (2002) 186:23-31.
   PubMed Web of Science ®Google Scholar
• COOPER CL, PARBHAKAR MA, ANGEL JB: Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin. Infect. Dis. (2002) 34:1259-1263.
   PubMed Web of Science ®Google Scholar
• ACETI A, PASQUAZZI C, ZECHINI B, DE BAC C: Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J. Acquir. Immune Defic. Syndr. (2002) 29:41-48.
   PubMed Web of Science ®Google Scholar
• MONFORTE ADE A, BUGARINI R, PEZZOTTI P et al.: Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J. Acquir. Immune Defic. Syndr. (2001) 28:114-123.
   PubMed Web of Science ®Google Scholar
• WALMSLEY S, BERNSTEIN B, KING M et al.; M98-863 study team: Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N. Engl. J. Med. (2002) 346:2039-2046.
   PubMed Web of Science ®Google Scholar
• VORA S, MICHON C, JUNET C et al.: Switch from indinavir to ritonavir-indinavir regimen in patients treated with highly active antiretroviral therapy co-infected with hepatitis C is not associated with alteration of liver function tests. AIDS (2000) 14:2795-2797.
   PubMed Web of Science ®Google Scholar
• MOYLE G: Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin. Ther. (2000) 22:911-936.
   PubMed Web of Science ®Google Scholar
• YAMANAKA H, GATANAGA H, KOSALARAKSA P et al.: Novel mutation of human DNA polymerase γ associated with mitochondrial toxicity induced by anti-HIV treatment. J. Infect. Dis. (2007) 195:1419-1425.
   PubMed Web of Science ®Google Scholar
• REED JC: Apoptosis-regulating proteins as targets for drug discovery. Trends Mol. Med. (2001) 7:314-319.
   PubMed Web of Science ®Google Scholar
• BERSON A, DE BECO V, LETTERON P et al.: Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology (1998) 114:764-774.
   PubMed Web of Science ®Google Scholar
• PESSAYRE D, BERSON A, FROMENTY B, MANSOURI A: Mitochondria in steatohepatitis. Semin. Liver Dis. (2001) 21:57-69.
   PubMed Web of Science ®Google Scholar
• DANSETTE PM, BONIERBALE E, MINOLETTI C, BEAUNE PH, PESSAYRE D, MANSUY D: Drug-induced immunotoxicity. Eur. J. Drug Metab. Pharmacokinet. (1998) 23:443-451.
   PubMed Web of Science ®Google Scholar
• BEAUNE P, DANSETTE PM, MANSUY D et al.: Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc. Natl. Acad. Sci. USA (1987) 84:551-555.
   PubMed Web of Science ®Google Scholar
• ROBIN MA, LE ROY M, DESCATOIRE V, PESSAYRE D: Plasma membrane cytochromes 450 as neoantigens and autoimmune targets in drug-induced hepatitis. J. Hepatol. (1997) 26(Suppl. 1):23-30.
   PubMedGoogle Scholar
• HAUTEKEETE ML, HORSMANS Y, VAN WAEYENBERGE C et al.: HLA association of amoxicillin-clavulanate-induced hepatitis. Gastroenterology (1990) 117:1181-1186.
   Google Scholar
• TRAUNER M, MEIER PJ, BOYER JL: Molecular pathogenesis of cholestasis. N. Engl. J. Med. (1998) 339:1217-1227.
   PubMed Web of Science ®Google Scholar
• TRAUNER M, FICKERT P, WAGNER M: MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin. Liver Dis. (2007) 27:77-98.
   PubMed Web of Science ®Google Scholar
• FOUNTAIN FF, TOLLEY E, CHRISMAN CR, SELF TH: Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest (2005) 128:116-123.
   PubMed Web of Science ®Google Scholar
• MADDREY WC: Drug-induced hepatotoxicity: 2005. J. Clin. Gastroenterol. (2005) 39(Suppl. 2):S83-S89.
   PubMed Web of Science ®Google Scholar
• MORGAN MY, RESHEF R, SHAH RR, OATES NS, SMITH RL, SHERLOCK S: Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut (1984) 25:1057-1064.
   PubMed Web of Science ®Google Scholar
• ALVAN G, BECHTEL P, ISELIUS L, GUNDERT-REMY U: Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. (1990) 39:533-537.
   PubMed Web of Science ®Google Scholar
• HUANG YS, CHERN HD, SU WJ et al.: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology (2003) 37:924-930.
   PubMed Web of Science ®Google Scholar
• BOURDI M, TINEL M, BEAUNE PH, PESSAYRE D: Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol. Pharmacol. (1994) 45:1287-1295.
   PubMed Web of Science ®Google Scholar
• RIEDER MJ, SHEAR NH, KANEE A, TANG BK, SPIELBERG SP: Prominence of slow acetylator phenotype among patients with sulfonamide hypersensitivity reactions. Clin. Pharmacol. Ther. (1991) 49:13-17.
   PubMed Web of Science ®Google Scholar
• HUANG YS, SU WJ, HUANG YH et al.: Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J. Hepatol. (2007) 47:128-134.
   PubMed Web of Science ®Google Scholar
• KAKUDA TN: Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. (2000) 22:685-708.
   PubMed Web of Science ®Google Scholar
• KRAMER JR, GIORDANO TP, SOUCHEK J, EL-SERAG HB: Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J. Hepatol. (2005) 42:309-314.
   PubMed Web of Science ®Google Scholar
• ARANZABAL L, CASADO JL, MOYA J et al.: Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin. Infect. Dis. (2005) 40:588-593.
   PubMed Web of Science ®Google Scholar
• DAY CP: Nash-related liver failure: one hit too many? Gastroenterology (2002) 97:1872-1874.
   Web of Science ®Google Scholar
• EL-SERAG HB, EVERHART JE: Diabetes increases the risk of acute hepatic failure. Gastroenterology (2002) 122:1822-1828.
   PubMed Web of Science ®Google Scholar
• TARANTINO G, CONCA P, BASILE V et al.: A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol. Res. (2007) 37:410-415.
   PubMed Web of Science ®Google Scholar
• UNGO JR, JONES D, ASHKIN K et al.: Anti-tuberculosis drug-induced hepatotoxicity: the role of hepatitis C virus and the human immunodeficiency virus. Am. J. Resp. Crit. Care Med. (1998) 157:1871-1876.
   PubMed Web of Science ®Google Scholar
• WONG WM, WU PC, YUEN MF et al.: Anti-tuberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology (2000) 31:201-206.
   PubMed Web of Science ®Google Scholar
• LINDON JC, KEUN HC, EBBELS TM, PEARCE JM, HOLMES E, NICHOLSON JK: The consortium for metabonomic toxicology (COMET): aims, activities and achievements. Pharmacogenomics (2005) 7:691-699.
   Google Scholar